Study of Immune Responses in Patients With Metastatic Melanoma

Phase 2

Withdrawn

• Conditions: Metastatic Melanoma

• Registration Number: NCT01416844
• Lead Sponsor: Providence Health & Services

Brief Summary

In this study, anti-OX40 will be given to patients with melanoma to find out how the immune system responds to treatment with anti-OX40. It is hoped that this treatment will cause an immune response against melanoma resulting in tumor regression, but this is not known at this time. Anti-OX40 is a large protein that can help immune cells that fight bacteria, viruses and cancer cells.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2011-08-12
• Study First Submitted QC: 2011-08-12
• Study First Posted: 2011-08-15
• Study Start: 2012-09
• Primary Completion: 2012-09
• Study Completion: 2012-09
• Status Verified: 2013-03
• Last Update Submitted: 2013-03-06
• Last Update Posted: 2013-03-07

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Patients with measurable or evaluable unresectable, stage IV metastatic melanoma. Either histologic or cytologic diagnosis is acceptable.

2. Eastern Cooperative Oncology Group (ECOG) performance status 0, or 1 (Appendix A.)

3. Age 18 years or above.

4. Laboratory values (performed within 28 days prior to enrollment) as follows:

   • WBC ≥2000/microliter
   • Absolute lymphocyte count >300/mm3
   • Serum creatinine <1.5 X upper limit of laboratory normal
   • Hgb >8g/dl (patients may be transfused to reach this level)
   • Hct > 24%
   • Platelets >100,000 cells/mm3
   • Total bilirubin <1.5 X upper limit of laboratory normal, unless due to Gilbert's disease
   • AST (SGOT)/ALT (SGPT) <2.5 X upper limit of laboratory normal
   • Alkaline phosphatase <2.5 X upper limit of laboratory normal
   • HIV Negative
   • Hepatitis B surface antigen Negative
   • Hepatitis C antibody Negative

5. Women of childbearing potential must have a negative pregnancy test and must avoid becoming pregnant while on treatment. Men must avoid fathering a child while on treatment. This exclusion is required due to the unknown toxicities that anti-OX40 may have on the forming fetus, spermatogenesis or the nursing child. Also, because pregnancy may impair immune function it may limit the treatment efficacy.

6. Ability to give informed consent and comply with the protocol. Patients with a history of psychiatric illness must be judged able to understand fully the investigational nature of the study and the risks associated with the therapy.

7. No active bleeding.

8. No clinical coagulopathy (INR <1.5, PT <16 seconds, PTT < 38 seconds).

9. Anticipated lifespan greater than 12 weeks.

10. Failed at least one prior medical therapy for metastatic melanoma.

Exclusion Criteria

1. Active infection.
2. History of or active autoimmune disease.
3. Prior mouse monoclonal antibody treatment.
4. Pregnant or lactating women, as treatment involves unforeseeable risks to the embryo or fetus.
5. Need for chronic maintenance oral steroids.
6. Active brain metastatic disease. Treated brain metastases with surgery, gamma-knife radiosurgery and/or whole brain radiation and stable for at least 4 weeks and off steroids are eligible.
7. Any medical or psychiatric condition that in the opinion of the PI would preclude compliance with study procedures.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Increased number of tumor antigen specific circulating T Cells	Screening (baseline) and Day 15	T Cells will be harvested by apheresis at baseline and Day 15 following anti-OX40 administration.

Trial Locations

Locations (1)

Providence Portland Medical Center; 🇺🇸 Portland, Oregon, United States